Andrew Brack

Scientist interested in preventing functional decline during aging. Program Manager at ARPA-H. Interests: Crypto, Everton FC and Boxing. Views are my own.

[Andrew Brack @BrackLab]

What if we had therapies to extend healthspan and prevent the onset of age related diseases? I’m excited to announce my first @ARPA_H program, PROSPR.
The goal is to develop validated surrogate biomarkers, new clinical endpoints and therapies to collectively extend healthspan by 20 years for all Americans.

[ARPA-H @ARPA_H]

What if we could predict age-induced health issues before they happen? Our new PROSPR program aims to identify biochemical and physiological markers, paving the way for faster, more targeted aging research. https://t.co/0euJylCcwa

[Michelle Kwok 💫 @michellebkwok]

Most VC is just asset management with better branding.

The 15th productivity SaaS. The third food delivery app. Consensus investing in whatever already worked last cycle.

This year we backed a company turning 55-year-old stem cells back to their embryonic state.

Another that vaporizes tumors without making a single incision.

One reprogramming cells like software to cure disease instead of just managing symptoms.

A brain-computer interface restoring motion to amputees.

Every single one sounded impossible until it wasn't.

The science is out there. Sitting in labs, underfunded, waiting for someone with the conviction to get behind it.

The job isn’t just writing a check, it’s also believing when almost nobody else does.

That's what VC looks like when it's aimed correctly.

Simply civilizational upside.

What's the most important science you think is criminally underfunded right now?

[Andrew Brack @BrackLab]

The pie is getting bigger

[STAT @statnews]

Longevity startup NewLimit raises $435 million ahead of first clinical trial https://t.co/AwO6qFUdVj

[Andrew Brack @BrackLab]

@CharlesMBrenner Enjoy the adventure

[Core Memory @corememory]

Go on. Look at these mice!!!!

They're old and hungover but cruising around like it ain't no thang.

NewLimit appears to have a therapy that reverses short and longterm damage from booze. Just remarkable results, heading to human trials next year.

We get into it all on the latest Core Memory podcast with Jacob Kimmel, the co-founder and president of NewLimit.

[Insilico Medicine @InSilicoMeds]

The Unexpected Challenge of Hiring "Experienced" AI Pharma Talent

"Many experienced hires have been living in a bubble and got used to being unproductive." In AI drug discovery, the real gap isn't credentials, it's the ability to actually produce. We don't need more press releases or research papers; we need drugs that work. It's time to burst the "unproductive bubble."

#AlexZhavoronkov #InvestingTips #PharmaAI #BiotechReality #VentureCapital

[Andrew Brack @BrackLab]

@jacobkimmel @newlimit @foundersfund @ThriveCapital @Greenoaks Awesome @jacobkimmel. Wonderful news

[Andrew Brack @BrackLab]

Couldn’t agree more, PROSPR🖖

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

"Live Long and Prosper" 🖖

Wonderful seeing Jose @cordeiro at the Berlin Life Summit before his longevity advocacy work at the European Parliament. To aid his mission, I gave him a copy of the Harvard Special Report on Longevity, a project I proudly served as medical editor for.

[Max Unfried @MaxUnfried]

Interested in Entropy & Aging?

Note that there will be an Entropy in Aging conference and workshop in Cologne end of August, enabled by the International Aging Entropy Open Research Network!

Attendance is free of charge and focused on intimate discussions!

https://t.co/fTfC0DKo3t

@Meyer_DH

[Andrew Brack @BrackLab]

@agingdoc1 Well done David

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

It’s here🌟

I served as Medical Editor for this 50-page report, to bring rigorous, evidence-based longevity science to a broad general audience.

Grateful to have contributed, excited to see the longevity conversation move further into the mainstream👇

🔗https://t.co/PMnUxOP18t

[Patrick Collison @patrickc]

Two conversations this weekend make me think that there's a vibe shift afoot in Silicon Valley around what one should work on and what is worthwhile.

Culturally, it feels like the moment is ripe for new frameworks:

• Davos expert morality is stale and discredited.
• It's also apparent that the "just be super based" Counter-Enlightenment is not really an answer. (Yes, woke went too far, but simply inverting it doesn't work.)
• EA is no longer the automatic default for smart people.
• There's increasing skepticism of slot and slop machine dynamics.

Overall, "what is worthy and valuable?" feels like it's becoming more central.

[Andrew Brack @BrackLab]

@MartinBJensen Time will tell, but it felt different.

[Andrew Brack @BrackLab]

I was honored to be involved in this important discussion on the clinical and regulatory path for gerotherapeutics. @ARPA_H, @reaganudall and @xprize. Thankyou to our @HHSGov colleagues at @US_FDA for your contribution.

[Foundation for FDA @reaganudall]

.@US_FDA Chief Scientist Dr. Steven Kozlowski provides opening remarks during our hybrid public meeting on Affecting the Aging Trajectory: Regulatory Constructs for Gerotheraeputic Drug, Biologic & Device Development.

[Andrew Brack @BrackLab]

@ladanuzhna FWIW, I’m with you and the non VCs. It’s where the puck is going.

[Andy Kilianski @AndyKilianski]

@rtnarch Not to mention a very sizable nondilutive investment from @ARPA_H! Very exciting!!

[Andrew Brack @BrackLab]

@ARPA_H Great team work with @reaganudall and @xprize

[Michael Koeris @mkoeris]

That's a good idea @FDA @FDACommissioner

[Robert Nelsen @rtnarch]

We need an Innovation Review Voucher, where a USA innovator (not others) can apply, based on their innovation in a drug category or molecule, for super fast regulatory approval, AND a transferable and subdividable 3 year commercial exclusivity, which covers the structure and close derivatives.

Applications would be 90 day decisions, with a standard that a reasonable person would conclude that the technology was used or copied by the entity. In practice, this should prevent USA innovation from being decimated via less funding flowing in (which hurts patients in the long run), and if the commercial delay is critically important the vouchers are tradeable, and can be granted to more than one party at the discretion of the holder, so patients are protected.

Prob have like ARPA H like structure or some new DOC panel to do it.